Meloxicam and Hypercoagulation - a phase IV clinical study of FDA data

Summary:

Hypercoagulation is reported as a side effect among people who take Meloxicam (meloxicam), especially for people who are female, 60+ old, also take Neurontin, and have Metastases to bone.

The phase IV clinical study analyzes which people have Hypercoagulation when taking Meloxicam. It is created by eHealthMe based on reports of 64,757 people who have side effects when taking Meloxicam from the FDA, and is updated regularly.

What is Meloxicam?

Meloxicam has active ingredients of meloxicam. It is often used in arthritis. eHealthMe is studying from 68,015 Meloxicam users. Check the latest studies of Meloxicam.

What is Hypercoagulation?

Hypercoagulation (increased tendency for clotting of the blood) is found to be associated with 400 drugs and 537 conditions by eHealthMe. Check the latest studies of Hypercoagulation.

On Jun, 13, 2026

64,757 people reported to have side effects when taking Meloxicam.
Among them, 25 people (0.04%) have Hypercoagulation.

Among these 25 people:

What is the gender of people who have Hypercoagulation when taking Meloxicam? *

female: 95.83 %
male: 4.17 %

What is the age of people who have Hypercoagulation when taking Meloxicam? *

What are other drugs people take besides Meloxicam? *

What are other side effects people have besides Hypercoagulation? *

Fatigue (feeling of tiredness): 22 people, 88.00%
Back Pain: 22 people, 88.00%
Joint Pain: 21 people, 84.00%
Chest Pain: 21 people, 84.00%
Fall: 20 people, 80.00%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 20 people, 80.00%
Swelling: 20 people, 80.00%
Gingival Oedema (swelling of gums): 19 people, 76.00%
Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung): 19 people, 76.00%
Osteosclerosis (an elevation in bone density): 19 people, 76.00%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 19 people, 76.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 12.00%
Weakness: 2 people, 8.00%
Back Pain: 2 people, 8.00%
Depression: 2 people, 8.00%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 8.00%
Insomnia (sleeplessness): 2 people, 8.00%
Neuropathy Peripheral (surface nerve damage): 2 people, 8.00%
Reflux Gastritis (a condition in which the lining of a person's stomach becomes inflamed as a result of exposure to bile): 2 people, 8.00%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Meloxicam and have Hypercoagulation?

- Check whether Hypercoagulation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Meloxicam:

Meloxicam (68,015 reports)

Browse all side effects of Meloxicam:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypercoagulation:

Hypercoagulation (400 drugs)

Browse all the conditions that are associated with Hypercoagulation:

Hypercoagulation (537 conditions)

Related publications that referenced our studies

Lai SW, Lin CL, Liao KF, "Association of Meloxicam Use with the Risk of Acute Pancreatitis: A Case–Control Study", Clinical drug investigation, 2015 Oct .
Lai SW, Lin CL, Liao KF, "Association of Meloxicam Use with the Risk of Acute Pancreatitis: A Case–Control Study", Clinical drug investigation, 2015 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on meloxicam (the active ingredients of Meloxicam) and Meloxicam (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.